News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They have cash until the end of Q3, but if additional funding isn't in place by then (at the latest) it's lights out. Shareholders should consider voting "against" a number of corporate incentives on the table. Officers should not be receiving bonuses this time around.
They have had countless secondaries over the years, but never an approved therapy. This company has been nothing more than a capital consuming beast created by Edward Lanphier, and he as well as others, mainly management taking shareholders to the cleaners, while they live in luxury! https://finance.yahoo.com/news/sangamo-therapeutics-announces-pricing-24-120500032.html
From the 10-K: ''Based on our current operating plan, our cash, cash equivalents and marketable securities as of December 31, 2023 are expected to allow us to meet our liquidity requirements only into the third quarter of 2024. Although we have been actively seeking, and continue to actively seek, substantial additional capital, including through public or private equity or debt financing, royalty financing or other sources, such as strategic collaborations and other direct investments in our programs, we have been unsuccessful in securing any such additional capital to date. As a result, we have explored, and continue to explore, whether filing for bankruptcy protection is in the best interest of our Company and our stakeholders.''
We'll be good when we attain compliance after the close on Thursday. God willing the shorts don't upend that! Then and only then will the fool of a CEO announce the earnings call.
SGMO under $2
SGMO new 52 week low
I quite agree with your assessment of clinical stage bio companies as expensive experiments.
Out of curiosity I checked the reverse stock split history for Sangamo and came up with zero, which I found interesting.
Ever since Amgen went public in 1984 investors have placed high hopes on the possibility of hitting the Big One.
The biotech, biomed, medical device sector is actually the largest sector in terms of available public traded companies in which one
can invest. More go public every week.
The stock has certainly experienced some dramatic ups and downs since 2000
SGMO new 52 week low
Over 28 years with no success, allowing others to overtake them, while they created an unsustainable infrastructure. They couldn't even license their AAV capsids or ZFP-TFs, instead having to settle for a nominal "evaluation agreements" with Prevail and Chroma.
Worse still, have around a year of cash on hand unless they decide to address their costs. Does anyone know when the company plans on breaking even? Will it be in '26 or '27 if their haemophilia therapy is approved in '25? Also, they will need to rise, and with the current price it's going to be (extremely) dilutive. If the therapy isn't approved, I don't see how the company isn't toast.
SGMO new 52 week low
SGMO new 52 week low
SGMO new 52 week low
SGMO new 52 week low
|
Followers
|
90
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1004
|
|
Created
|
09/09/04
|
Type
|
Free
|
| Moderators | |||
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
AI
